Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15731292 | 0.92 | CA2 (0.56) | CA2ALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL10598855 | 0.91 | CA2 (0.53) | CA2ALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL14125872 | 0.91 | CA2 (0.70) | CA2ALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL20838318 | 0.87 | CA2 (0.48) | CA2ALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL10892809 | 0.86 | CA2 (0.63) | CA2ALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL14125668 | 0.86 | CA2 (0.63) | CA2ALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL20838317 | 0.84 | TDP1 (0.45) | CA2ALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL19085418 | 0.84 | CA2 (0.61) | CA2ALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL29133311 | 0.84 | CA2 (0.61) | CA2ALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL15731294 | 0.83 | CA2 (0.60) | CA2ALDH1A1CYP3A4TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10618856-B2 | Methods for producing cyclic and acyclic ketones | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-04-14 | — | — | US | disclosed |
| US-20190127292-A1 | METHODS FOR PRODUCING CYCLIC AND ACYCLIC KETONES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-05-02 | — | — | US | disclosed |
| US-10207961-B2 | Methods for producing cyclic and acyclic ketones | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180170824-A1 | METHODS FOR PRODUCING CYCLIC AND ACYCLIC KETONES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-06-21 | — | — | US | disclosed |
| US-9790444-B2 | Methods to produce fuels | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790444-B2 | Methods to produce fuels | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-10-17 | — | — | US | disclosed |
| EP-3122710-A2 | METHODS FOR PRODUCING CYCLIC AND ACYCLIC KETONES | The Regents of the University of California (US) | 2017-02-01 | — | — | EP | disclosed |
| US-20160152907-A1 | METHODS TO PRODUCE FUELS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-06-02 | — | — | US | disclosed |
| US-20160152907-A1 | METHODS TO PRODUCE FUELS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-06-02 | — | — | US | disclosed |
| WO-2015148412-A2 | METHODS FOR PRODUCING CYCLIC AND ACYCLIC KETONES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-10-01 | — | — | WO | disclosed |
| US-20140137465-A1 | METHOD TO CONVERT FERMENTATION MIXTURE INTO FUELS | BP CORPORATION NORTH AMERICA INC. (US) | 2014-05-22 | — | — | US | disclosed |
| WO-2012096813-A1 | IMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2012-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10618856-B2 | Methods for producing cyclic and acyclic ketones | PCCA, BCKDK, DECR2 | CA2 3691/4885ALDH1A1 1262/4885CYP3A4 307/4885 |
| US-20180170824-A1 | METHODS FOR PRODUCING CYCLIC AND ACYCLIC KETONES | PCCA, BCKDK, DECR2 | CA2 3691/4885ALDH1A1 1262/4885CYP3A4 307/4885 |
| US-10207961-B2 | Methods for producing cyclic and acyclic ketones | PCCA, BCKDK, DECR2 | CA2 3691/4885ALDH1A1 1262/4885CYP3A4 307/4885 |
| US-20190127292-A1 | METHODS FOR PRODUCING CYCLIC AND ACYCLIC KETONES | PCCA, BCKDK, DECR2 | CA2 3691/4885ALDH1A1 1262/4885CYP3A4 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.